How Much Can You Save?
Speak With a Copay Assistance Specialist
We accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances.
Get Started in Minutes
How Trazimera Copay Assistance Works
1 – Check Your Coverage/Benefits Verification
Our team of expert billers finds the best avenues of coverage that minimize out-of-pocket costs.
2 – Transfer Prescription to AmeriPharma
We process your prescription by working with your previous pharmacy or prescriber, making the transition quick and easy.
3 – Prior Authorization
Our team of specialists obtains approval from your insurance companies within 24 to 72 hours.
4 – Copay Assistance & Financial Aid
We secure financial aid and decrease copays, out-of-pocket expenses, and high deductibles. To date, AmeriPharma Specialty Care has secured $55 million in financial assistance for our patients.
5 – Nursing Care Coordination
AmeriPharma puts your schedule and home environment first when scheduling and coordinating one of our specialized nurses for your in-home infusions.
6 – Delivery Coordination
Medications are always delivered in strict compliance with the specific requirements for immune globulin shipping. Next-day and overnight cold-chain deliveries are coordinated around your schedule.
Speak With a Specialist
We accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances. Call us to find out more about your coverage.
What Is Trazimera and How Does It Work?
Trazimera is a medication with the generic name trastuzumab-qyyp. It is a biosimilar medication to trastuzumab and belongs to the class of medications known as monoclonal antibodies. Trastuzumab was first approved by the FDA on September 25, 1998, for the treatment of patients with metastatic breast cancer whose tumors overexpress the HER-2 protein and who have received one or more chemotherapy regimens for their metastatic disease. It was also approved to be used in combination with another chemotherapy medication called paclitaxel for the treatment of patients with metastatic breast cancer whose tumors overexpress HER-2 protein and who have not received chemotherapy for their metastatic disease. Trazimera was approved as a biosimilar to trastuzumab on March 11, 2019.
Trazimera is a monoclonal antibody that binds to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER-2). By doing so, it triggers cell destruction of those cancerous cells that are expressing the HER-2 protein. This is known as antibody-dependent cellular cytotoxicity, and it inhibits the rapid increase in the number of cells that overexpress HER-2 protein (cancerous cells).
Schedule a Consultation
We accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances. Call us to find out more about your coverage.
What Is Trazimera Used To Treat?
Trazimera is FDA-approved for the treatment of:
- Breast cancer as an adjuvant treatment: Adjuvant treatment of HER2-overexpressing breast cancer, as part of a treatment regimen consisting of cyclophosphamide, doxorubicin, and either docetaxel or paclitaxel, or as part of a treatment regimen with docetaxel and carboplatin, or as a single agent following multimodality anthracycline-based therapy.
- Metastatic Breast Cancer:
- First-line treatment of HER2-overexpressing metastatic breast cancer (in combination with paclitaxel).
- As a single-agent treatment of HER2-overexpressing breast cancer in patients who have previously received one or more chemotherapy regimens for metastatic disease.
- Metastatic Gastric Cancer: Treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma (in combination with cisplatin and either capecitabine or 5-fluorouracil) in patients who have not received prior treatment for metastatic disease.
Patients should be selected for breast and gastric cancer therapy based on an approved companion diagnostic test for tumor specimens for HER2 overexpression, or HER2 gene amplification.
Copay and Financial Assistance
AmeriPharma Specialty Care alleviates financial burdens for patients and their families
Advanced software locates funding sources to match you with top-dollar foundation programs
One of our copay assistance specialists will assist with the application process
Automatic updates will be sent to you and your physician on the status of the funding
Speak With a Specialist
We accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances. Call us to find out more about your coverage.
Trazimera Side Effects
- Decreased left ventricular ejection fraction
- High blood pressure
- Arrhythmia
- Heart failure
- Edema (swelling)
- Palpitations
- Fast heart rate
- Skin rash
- Acne
- Nail disease
- Itching
- Abdominal pain
- Anorexia (an eating disorder)
- Diarrhea
- Nausea
- Vomiting
- Constipation
- Indigestion
- Various infections (influenza, herpes simplex, upper respiratory tract infections, and others)
- Chills
- Dizziness
- Headache
- Insomnia
- Depression
- Neuropathy (weakness, numbness, and pain from nerve damage, usually in the hands and feet)
- Joint pain
- Muscle spasm
- Muscle and bone pain
- Flu-like symptoms
These are not all the side effects that can happen with Trazimera. Speak to your pharmacist or doctor if you would like to know more about Trazimera.
Schedule a Consultation
We accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances. Call us to find out more about your coverage.
Trazimera Dosing Information
Trazimera is available as a vial for reconstitution and intravenous infusion. The available vial sizes are as follows:
- 150 mg vial
- 420 mg vial
Your Trazimera dose depends on your body weight and the indication you’re being treated for:
- Trazimera is usually given as a higher loading dose (4 – 8 mg/kg) followed by a lower maintenance dose (2 – 6 mg/kg).
- The dose is then diluted in normal saline and is then infused through a catheter that gets inserted into a vein in the arm.
- Infusions usually take about 90 minutes followed by a period of observation for any infusion-related reactions. Maintenance doses may sometimes be infused over shorter periods of time depending on prior infusions being well-tolerated.
Patients who receive Trazimera need to be observed closely during the infusion for fever, chills, or other infusion-related symptoms. Treatment with acetaminophen, diphenhydramine, or meperidine is usually effective for managing infusion-related events.
Speak to your pharmacist or doctor for more information regarding Trazimera.